Changes in schizophrenia symptoms, tryptophan metabolism, neuroinflammation and the GABA-glutamate loop: A pilot study

Résumé

Methods Study design and assessmentsTwenty-eight black African patients with a diagnosis of schizophrenia (DSM-5 criteria) were recruited upon admission to a psychiatric hospital in the Dr Kenneth Kaunda District, North West province, South Africa, between January 2021 and June 2022.Patients were either newly diagnosed (first-episode psychosis) or had relapsed and had been antipsychotic free (i.e. did not receive any antipsychotics at dosages indicated for antipsychotic effects for at least 6 months prior to admission).Exclusion criteria included non-African descent, neurological disorders, head trauma, pregnancy, lactation, tympanum temperatures >37°C, substance abuse and tested positive for coronavirus disease 2019 (COVID-19).Patients exhibiting destructive, Changes in schizophrenia symptoms, tryptophan metabolism, neuroinflammation and the GABA-glutamate loop: A pilot study Read online:Scan this QR code with your smart phone or mobile device to read online.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0